Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.

In order to improve the predictability of dissolution testing new apparatuses have been proposed that mimic hydrodynamic and mechanical conditions in the gastrointestinal tract. In this study tested were four different nifedipine extended release (ER) formulations using the paddle apparatus and the reciprocating cylinder as pharmacopoeial test devices as well as two newly developed test apparatuses: the rotating beaker apparatus and the dissolution stress test apparatus. Investigated were Adalat OROS in strengths of 30 and 60 mg, and two hydrophilic matrix formulations: 60 mg nifedipine Coral and Nifedipin Sandoz 40 mg retard. The results demonstrate that the dissolution characteristic of the ER tablets is strongly dependent on the applied test conditions. The dosage form related food effects for Coral 60 mg tablets that were previously observed in human bioequivalence studies could be predicted with the two non-compendial dissolution test devices. The dissolution of Sandoz 40 mg tablets was very sensitive to all applied test conditions. The stable drug delivery characteristics of Adalat OROS observed in numerous in vivo studies was also observed in all of the dissolution tests. In conclusion, the present study shows that besides pH dependency the aspect of the mechanical robustness may be an essential factor affecting the dissolution characteristic of hydrogel matrix formulations.

[1]  James C. Sexton,et al.  Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate, mixing patterns, and fluid velocities , 2004, AAPS PharmSciTech.

[2]  J. Brasseur,et al.  A Novel in Vitro and Numerical Analysis of Shear-Induced Drug Release from Extended-Release Tablets in the Fed Stomach , 2005, Pharmaceutical Research.

[3]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[4]  E. Brendel,et al.  Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. , 2008, Clinical Therapeutics.

[5]  E. Brendel,et al.  Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  James C. Sexton,et al.  Simulating the hydrodynamic conditions in the united states pharmacopeia paddle dissolution apparatus , 2008, AAPS PharmSciTech.

[7]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[8]  N. Peppas,et al.  Drug diffusion front movement is important in drug release control from swellable matrix tablets. , 1995, Journal of pharmaceutical sciences.

[9]  V. Pillay,et al.  Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[10]  R. B. Walker,et al.  The Effects of Buffer Molarity, Agitation Rate, and Mesh Size on Verapamil Release from Modified-Release Mini-Tablets Using USP Apparatus 3 , 2007 .

[11]  C. Toal.  Formulation Dependent Pharmacokinetics—Does the Dosage Form Matter for Nifedipine? , 2004, Journal of cardiovascular pharmacology.

[12]  F. Muzzio,et al.  Shear-induced variability in the United States pharmacopeia apparatus 2: Modifications to the existing system , 2005, The AAPS Journal.

[13]  T. Walley,et al.  Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers. , 1987, British journal of clinical pharmacology.

[14]  R. Schall,et al.  The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. , 2002, British journal of clinical pharmacology.

[15]  O. Corrigan,et al.  Swelling and erosion properties of hydroxypropylmethylcellulose (Hypromellose) matrices--influence of agitation rate and dissolution medium composition. , 2004, International journal of pharmaceutics.

[16]  N. Hosten,et al.  Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.

[17]  Ken-ichi Yamamoto,et al.  Application of model-independent and model analysis for the investigation of effect of drug solubility on its release rate from hydroxypropyl methylcellulose sustained release tablets , 1996 .

[18]  A. Beckett,et al.  Improved Hydrodynamics for USP Apparatus 2 , 1996 .

[19]  H. Schoemaker,et al.  Intraindividual Variability in Nifedipine Pharmacokinetics and Effects in Healthy Subjects , 1992, Journal of clinical pharmacology.

[20]  K. Ewe,et al.  Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector , 1991, Digestive Diseases and Sciences.

[21]  Clive G. Wilson,et al.  Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  R. Fisher,et al.  Gastric emptying of a non‐digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[23]  S. Aoki,et al.  Determination of the mechanical impact force in the in vitro dissolution test and evaluation of the correlation between in vivo and in vitro release , 1993 .

[24]  M. A. Matlib,et al.  Pharmacology of calcium antagonists. , 1985, The American journal of cardiology.

[25]  Y. Seta,et al.  A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. , 2000, International journal of pharmaceutics.

[26]  A. Karim,et al.  Food‐induced changes in theophylline absorption from controlled‐release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption , 1985, Clinical pharmacology and therapeutics.

[27]  R. Fassihi,et al.  Release characterization of dimenhydrinate from an eroding and swelling matrix: selection of appropriate dissolution apparatus. , 2005, International journal of pharmaceutics.

[28]  Lutz Trahms,et al.  Magnetic Marker Monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. , 2005, Advanced drug delivery reviews.

[29]  S. Qureshi.  A New Crescent-shaped Spindle for Drug Dissolution Testing—But Why a New Spindle? , 2004 .

[30]  M. Alpsten,et al.  Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[31]  James A. Rogers,et al.  Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test , 1997 .

[32]  R. Foster,et al.  Erratum to The nifedipine gastrointestinal therapeutic system (GITS) : evaulation ofpharmaceutical. pharmacokinetic and pharmacological properties , 1996 .

[33]  J. Dressman,et al.  Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.

[34]  J. Dressman,et al.  Characterization of the Human Upper Gastrointestinal Contents Under Conditions Simulating Bioavailability/Bioequivalence Studies , 2006, Pharmaceutical Research.